6:38
Follicular lymphoma: is RELEVANCE relevant?
Frank Morschhauser
3:43
Predictors of outcome for follicular lymphoma
Anna Schuh
2:01
Safety data for the PI3Kδ inhibitor umbralisib for lymphoid malignancies
Susan O’Brien
2:00
Long-term follow-up results of the ZUMA-1 trial of anti-CD19 CAR T-cells for non-Hodgkin lymphoma
Sattva Neelapu
iwNHL 2017: The future of lymphoma research and treatment
Catherine Bollard et al.
2:31
Chemotherapy-free approaches in CLL, follicular lymphoma and DLBCL
Christian Buske
5:37
Key abstracts being presented at ASH 2017
Anas Younes
2:23
The GALLIUM study
Robert Marcus
3:02
What are the causes of fatigue after cancer treatment?
Marije van der Lee
3:21
Holistic care in the management of asymptomatic follicular lymphoma
George Follows
4:31
Overview of the GALLIUM study
Wolfgang Hiddemann
2:49
Overview of classical therapies for follicular lymphoma
Andrew Lister
4:14
Novel therapies for the treatment of CLL, MCL and FL
Nathan Fowler
1:55
Ibrutinib in combination with rituximab – the future of treating FL
Nathan Fowler
1:53
Relapsed follicular lymphoma: hope from a non-chemotherapy regimen of lenalidomide and obinutuzumab
Nathan Fowler
2:46
Is obinutuzumab our key to improving the treatment of FL?
Wolfgang Hiddemann
VJHemOnc is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

The content of VJHemOnc is intended for healthcare professionals